Last updated: April 26, 2026
What is the case and what claims are at issue?
Case: Boehringer Ingelheim Pharmaceuticals Inc. v. Aurobindo Pharma Ltd.
Docket: 1:18-cv-01757
Court: U.S. District Court (federal)
Parties: Boehringer Ingelheim Pharmaceuticals Inc. (plaintiff) vs. Aurobindo Pharma Ltd. (defendant)
The case is a Hatch-Waxman patent litigation framework filing tied to a proposed generic launch that Boehringer treated as infringing one or more listed patents. The litigation posture is consistent with a U.S. patent infringement action brought to block approval or entry of a generic product based on certification and regulatory linkage under the Orange Book system.
What is the core litigation posture (regulatory-to-patent linkage)?
In Hatch-Waxman disputes, the infringement claim typically tracks:
- Orange Book-listed patents for the branded product
- The defendant’s ANDA filing (and the specific Paragraph IV or equivalent certification)
- A set of asserted U.S. patents and claims corresponding to product composition, method-of-use, formulation, or process
In this matter, Boehringer’s litigation position hinges on the standard Hatch-Waxman mechanics: the generic’s ANDA triggers infringement theories on one or more listed patents, and the court’s decision determines the timing of generic market entry.
Which patents are asserted and what infringement theory is used?
No complete, accurate set of asserted patents, claim groupings, or infringement theories is available in the provided materials. A litigation summary that names specific asserted U.S. patents, identifies asserted claims, or describes claim constructions without that record would risk material errors.
What happened procedurally (timeline and major events)?
A procedural timeline requires docket-level facts (for example: complaint filing date, answers, motions to dismiss, Markman scheduling, claim construction orders, summary judgment rulings, trial dates, stipulations, or dismissal/settlement). Those details are not included in the input. Without them, an events-by-date summary would not be complete or reliable.
How does this case fit within Boehringer Ingelheim’s typical patent strategy in generics challenges?
Boehringer’s enforcement pattern in Hatch-Waxman disputes usually centers on:
- Early, claim-focused infringement assertions tied to Orange Book listings
- Priority on claim construction to narrow or preserve infringement positions
- Use of clinical and regulatory context (when relevant) to support the asserted claim scope
- Leveraging injunction and timing leverage to pressure resolution prior to launch
This case aligns with that enforcement model: Boehringer initiates litigation against an ANDA filer to prevent entry based on patent infringement allegations.
What is the business impact if Boehringer wins vs. loses?
In Hatch-Waxman cases, the payoff structure is largely driven by regulatory timing:
- If Boehringer prevails on infringement and the relevant remedies issue: the generic’s pathway is delayed, and market exclusivity or patent protection extends.
- If the court rejects Boehringer’s patent position (invalidity and/or non-infringement): the generic’s approval and potential entry typically accelerate, compressing branded revenue.
The actual magnitude depends on the specific patents, remaining statutory life, and any settlement terms, none of which are provided here.
What does Aurobindo’s likely defensive posture look like?
Common defenses in this posture include:
- Non-infringement (product design differences)
- Invalidity (anticipation/obviousness, lack of written description, indefiniteness, statutory subject matter)
- Procedural defenses tied to ANDA certification scope or standing
Aurobindo’s exact defenses and the specific invalidity grounds asserted in this case are not contained in the provided materials.
Why this case matters for investors and R&D planners
Even without the docket record, two clear investment signals often emerge from Hatch-Waxman litigation:
- Jurisdictional and timing leverage: early injunction risk can shift generics’ economics and branded expectations.
- Patent portfolio health: the case outcome indicates whether the asserted Orange Book patents remain enforceable and whether the technology claims withstand both construction and validity scrutiny.
Key Takeaways
- Boehringer Ingelheim Pharmaceuticals Inc. v. Aurobindo Pharma Ltd. (1:18-cv-01757) is a Hatch-Waxman patent infringement dispute linked to an ANDA and Orange Book-listed patents.
- The litigation’s commercial function is to determine whether the proposed generic can enter during the branded patent window.
- A complete, decision-grade summary of asserted patents, claim constructions, rulings, and final resolution cannot be produced from the information provided.
FAQs
1) Is this case an ANDA Paragraph IV dispute?
The case type and posture are consistent with Hatch-Waxman generics patent litigation tied to ANDA certification, but specific Paragraph IV details are not present in the provided materials.
2) What remedies are typically sought in this type of case?
Branded plaintiffs typically seek an injunction preventing generic launch tied to infringement findings and relevant statutory remedies in Hatch-Waxman actions.
3) What does the court usually decide in these cases?
The court typically addresses infringement and validity through claim construction, claim comparison to the accused product, and invalidity challenges.
4) How does a settlement usually affect outcomes?
Hatch-Waxman settlements often resolve timing by licensing and/or agreed entry dates; exact settlement terms require docket or agreement records not provided here.
5) What is the practical investor takeaway?
Outcome determines market entry timing and thus revenue and pipeline assumptions, but quantifying impact requires the asserted patent set and the final judgment or settlement terms.
References (APA)
[1] Boehringer Ingelheim Pharmaceuticals Inc. v. Aurobindo Pharma Ltd., No. 1:18-cv-01757 (U.S. District Court).
